![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Bernhardt, Alexander M. 
ORCID: https://orcid.org/0000-0002-2572-5062; Longen, Sebastian; Trossbach, Svenja V.; Rossi, Marcello; Weckbecker, Daniel; Schmidt, Felix; Jäck, Alexander; Katzdobler, Sabrina ORCID: https://orcid.org/0000-0002-3512-5984; Fietzek, Urban M.; Weidinger, Endy; Palleis, Carla ORCID: https://orcid.org/0000-0002-4331-8145; Ruf, Viktoria; Baiardi, Simone; Parchi, Piero; Höglinger, Günter U. ORCID: https://orcid.org/0000-0001-7587-6187; Matthias, Torsten; Levin, Johannes ORCID: https://orcid.org/0000-0001-5092-4306 und Giese, Armin
(2025):
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.
In: Acta Neuropathologica, Bd. 149, 20
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-2572-5062; Longen, Sebastian; Trossbach, Svenja V.; Rossi, Marcello; Weckbecker, Daniel; Schmidt, Felix; Jäck, Alexander; Katzdobler, Sabrina ORCID: https://orcid.org/0000-0002-3512-5984; Fietzek, Urban M.; Weidinger, Endy; Palleis, Carla ORCID: https://orcid.org/0000-0002-4331-8145; Ruf, Viktoria; Baiardi, Simone; Parchi, Piero; Höglinger, Günter U. ORCID: https://orcid.org/0000-0001-7587-6187; Matthias, Torsten; Levin, Johannes ORCID: https://orcid.org/0000-0001-5092-4306 und Giese, Armin
(2025):
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.
In: Acta Neuropathologica, Bd. 149, 20
[PDF, 1MB]
Levin, Johannes; Sing, Nand; Melbourne, Sue; Morgan, Amber; Mariner, Carla; Spillantini, Maria Grazia; Wegrzynowicz, Michal; Dalley, Jeffrey W.; Langer, Simon; Ryazanov, Sergey; Leonov, Andrei; Griesinger, Christian; Schmidt, Felix; Weckbecker, Daniel; Prager, Kai; Matthias, Torsten und Giese, Armin
(2022):
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind placebo-controlled phase 1a trial.
In: eBioMedicine, Bd. 80, 104021
[PDF, 612kB]